U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H15F2NO2
Molecular Weight 375.3675
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BREQUINAR

SMILES

CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C3=CC=C(C=C3)C4=C(F)C=CC=C4

InChI

InChIKey=PHEZJEYUWHETKO-UHFFFAOYSA-N
InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)

HIDE SMILES / InChI
Molecular Formula C23H15F2NO2
Molecular Weight 375.3675
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Brequinar had been in phase II clinical trials by Bristol-Myers Squibb for the treatment of cancer and transplant rejection. However, this research has been discontinued. Brequinar had been also in preclinical studys for the treatment of cytomegalovirus infections. However, this research has been discontinued.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 10.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
2600 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 1
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
DLT: Thrombocytopenia, Leucopenia...
Disc. AE: Anemia...
Other AEs: Stomatitis...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 100%)
Leucopenia (grade 2, 100%)
AEs leading to
discontinuation/dose reduction:
Anemia (grade 1, 100%)
Other AEs:
Stomatitis (grade 3, 100%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
210 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 210 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 210 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
unhealthy, ADULT
n = 5
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
DLT: Thrombocytopenia, Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 20%)
Thrombocytopenia (grade 3, 40%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
2300 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2300 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2300 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
DLT: Maculopapular rash, Skin eruption...
Other AEs: Thrombocytopenia...
Dose limiting toxicities:
Maculopapular rash (grade 3, 33.3%)
Skin eruption (grade 3, 33.3%)
Mucositis (grade 3, 33.3%)
Other AEs:
Thrombocytopenia (grade 3, 66.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
600 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 600 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 600 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Other AEs: Anemia, Stomatitis...
Other AEs:
Anemia (grade 3, 25%)
Stomatitis (grade 3, 25%)
Leucopenia (grade 2, 25%)
Thrombocytopenia (grade 4, 50%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
850 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 850 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 850 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Other AEs: Thrombocytopenia, Stomatitis...
Other AEs:
Thrombocytopenia (grade 3, 25%)
Stomatitis (grade 3, 25%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
350 mg/m2 1 times / day multiple, intravenous
Studied dose
Dose: 350 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 350 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
unhealthy, ADULT
n = 1
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
AEs

AEs

AESignificanceDosePopulation
Anemia grade 1, 100%
Disc. AE
2600 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 1
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Leucopenia grade 2, 100%
DLT, Disc. AE
2600 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 1
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Stomatitis grade 3, 100%
2600 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 1
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Thrombocytopenia grade 4, 100%
DLT, Disc. AE
2600 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 1
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Thrombocytopenia grade 3, 40%
DLT
210 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 210 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 210 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
unhealthy, ADULT
n = 5
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
Thrombocytopenia grade 4, 20%
DLT
210 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 210 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 210 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
unhealthy, ADULT
n = 5
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/8499153
Page: p.986
Maculopapular rash grade 3, 33.3%
DLT, Disc. AE
2300 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2300 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2300 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Mucositis grade 3, 33.3%
DLT, Disc. AE
2300 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2300 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2300 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Skin eruption grade 3, 33.3%
DLT, Disc. AE
2300 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2300 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2300 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Thrombocytopenia grade 3, 66.7%
2300 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2300 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2300 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1406, 1407
Leucopenia grade 2, 25%
600 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 600 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 600 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Anemia grade 3, 25%
600 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 600 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 600 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Stomatitis grade 3, 25%
600 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 600 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 600 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Thrombocytopenia grade 4, 50%
600 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 600 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 600 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Stomatitis grade 3, 25%
850 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 850 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 850 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Thrombocytopenia grade 3, 25%
850 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 850 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 850 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/2591433
Page: p.1407
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY113766
https://www.001chemical.com/chem/search?q=DY113766
1PlusChem LLC
1P006SVQ
https://www.1pchem.com/search?query=1P006SVQ
A2B Chem
AD16566
http://a2bchem.com/prod/AD16566
A2B Chem
AI68899
http://a2bchem.com/prod/AI68899
AA Blocks
AA006SCA
http://aablocks.com/goods/Goods/detail?id=AA006SCA
AK Scientific
X5917
https://aksci.com/item_detail.php?cat=X5917
Achemo Scientific Limited
AC-89615
http://www.achemo.com/search/?Keyword=AC-89615
Alfa Chemistry
278939
http://www.alfa-chemistry.com/search.aspx?q=278939
Alfa Chemistry
ACM96201886
http://www.alfa-chemistry.com/search.aspx?q=ACM96201886
Ambeed
A155500
http://www.ambeed.com/search/Search.html?keyword=A155500
Ambeed
A207630
http://www.ambeed.com/search/Search.html?keyword=A207630
AstaTech
F52273
http://astatechinc.com/CPSResult.php?CRNO=F52273
BLD Pharm
BD116738
http://www.bldpharm.com/search/Search.html?keyword=BD116738
BLD Pharm
BD118679
http://www.bldpharm.com/search/Search.html?keyword=BD118679
BOC Sciences
96187-53-0
http://www.bocsci.com/description.asp?cas=96187-53-0
BOC Sciences
96201-88-6
http://www.bocsci.com/description.asp?cas=96201-88-6
Chem Scene
CS-7842
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-7842
ChemShuttle
101293
https://www.chemshuttle.com/catalogsearch/result/?q=101293
Combi-Blocks
QN-0134
http://www.combi-blocks.com/cgi-bin/find.cgi?QN-0134
Debye Scientific
DB-080409
https://www.debyesci.com/index.php?id=product&ext[cno]=DB-080409
Enamine
EN300-263943
https://www.enaminestore.com/catalog/EN300-263943
Excenen
EX-A1515
http://www.excenen.com/searchresultlist.php?id=EX-A1515
Fluorochem
80292
http://www.fluorochem.co.uk/Products/Product?code=080292
Fluoropharm
YF10042
http://www.fluoropharm.com/product/YF10042.html
KeyOrganics
AS-74463
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-74463
KeyOrganics
DS-15411
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=DS-15411
Lab Network
LN00191481
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00191481
Lab Network
LN03271013
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN03271013
Lab Seeker
SC-55381
http://www.labseeker.com/search.php?keywords=SC-55381&category=0
Matrix Scientific
93124
http://www.matrixscientific.com/093124.html
MedChem Express
HY-108325
https://www.medchemexpress.com/search.html?q=HY-108325&ft=&fa=&fp=
MolPort
MolPort-006-169-119
https://www.molport.com/shop/molecule-link/MolPort-006-169-119
MolPort
MolPort-028-720-353
https://www.molport.com/shop/molecule-link/MolPort-028-720-353
Molcore
MC113766
http://www.molcore.com/CatMC113766.html
MuseChem
M008880
https://www.musechem.com/product/M008880.html
ShangHai Biochempartner
BCP06006
http://www.biochempartner.com/search_BCP06006
TargetMol
T5013
https://www.targetmol.com/search?keyword=T5013
eMolecules
300620155
https://orderbb.emolecules.com/search/#?query=300620155
eMolecules
43451776
https://orderbb.emolecules.com/search/#?query=43451776
eMolecules
44786255
https://orderbb.emolecules.com/search/#?query=44786255
eNovation Chemicals
D621765
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D621765&searchbtn.x=0&searchbtn.y=0
eNovation Chemicals
D759561
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D759561&searchbtn.x=0&searchbtn.y=0
mcule
MCULE-7590091357
https://mcule.com/MCULE-7590091357/
mcule
MCULE-7868113779
https://mcule.com/MCULE-7868113779/
PubMed

PubMed

TitleDatePubMed
Patents

Patents

JP4606172B2
28

Sample Use Guides

In Vivo Use Guide
Advanced melanoma: Brequinar was given at a median weekly dose of 1200 mg/m2 intravenously.
Route of Administration: Intravenous
In Vitro Use Guide
10 uM of brequinar sodium completely inhibited the dihydroorotate-induced oxygen consumption of rat liver mitochondria.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:52:19 GMT 2023
Edited
by admin
on Sat Dec 16 16:52:19 GMT 2023
Record UNII
5XL19F49H6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BREQUINAR
INN   MI   WHO-DD  
INN  
Official Name English
4-QUINOLINECARBOXYLIC ACID, 6-FLUORO-2-(2'-FLUORO(1,1'-BIPHENYL)-4-YL)-3-METHYL-
Common Name English
Brequinar [WHO-DD]
Common Name English
brequinar [INN]
Common Name English
6-FLUORO-2-(2'-FLUORO-4-BIPHENYLYL)-3-METHYL-4-QUINOLINECARBOXYLATE
Systematic Name English
BREQUINAR [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1557
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
NCI_THESAURUS C2169
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL38434
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
SMS_ID
100000088660
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
CHEBI
177387
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
NCI_THESAURUS
C1560
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
MERCK INDEX
m2646
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY Merck Index
EVMPD
SUB05885MIG
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID00242165
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
DRUG BANK
DB03523
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
CAS
96187-53-0
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
WIKIPEDIA
Brequinar
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
PUBCHEM
57030
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
MESH
C046943
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
FDA UNII
5XL19F49H6
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
INN
6204
Created by admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
PRIMARY
Related Record Type Details
DIHYDROOROTATE DEHYDROGENASE (QUINONE), MITOCHONDRIAL
TARGET -> INHIBITOR
Structure of BREQUINAR SODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of BREQUINAR
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966